Drugs / FluLaval® Quadrivalent
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01974895 | Oct 2013 → Feb 2014 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT02242643 | Oct 2014 → Mar 2015 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01440387 | Sep → Oct 2011 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01218308 | Dec 2010 → Jan 2012 | influenza | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FluLaval Quadrivalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01218308 ↗ |
| Modality | Vaccine | “candidate inactivated quadrivalent influenza vaccine (QIV)” PMID 24328444 ↗ Dec 2013 |
| Route | Intramuscular | “The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.” NCT01218308 ↗ |